×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ONC – beigene, ltd. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ONC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
08:13 am
onc
Beigene, Ltd. (NASDAQ: ONC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock.
Low
Report
Beigene, Ltd. (NASDAQ: ONC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock.
4/3
06:00 am
onc
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
Low
Report
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
3/18
12:02 pm
onc
Beigene, Ltd. (NASDAQ: ONC) was given a new $259.00 price target on by analysts at Sanford C. Bernstein.
Low
Report
Beigene, Ltd. (NASDAQ: ONC) was given a new $259.00 price target on by analysts at Sanford C. Bernstein.
3/10
11:11 am
onc
Beigene, Ltd. (NASDAQ: ONC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Beigene, Ltd. (NASDAQ: ONC) had its "buy" rating re-affirmed by analysts at Guggenheim.
3/10
11:09 am
onc
Beigene, Ltd. (NASDAQ: ONC) was given a new $348.00 price target on by analysts at JMP Securities.
Low
Report
Beigene, Ltd. (NASDAQ: ONC) was given a new $348.00 price target on by analysts at JMP Securities.
3/4
06:40 am
onc
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy [Yahoo! Finance]
Low
Report
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy [Yahoo! Finance]
3/4
06:00 am
onc
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
Low
Report
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
3/3
08:10 am
onc
Beigene, Ltd. (NASDAQ: ONC) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $320.00 price target on the stock, up previously from $207.00.
Medium
Report
Beigene, Ltd. (NASDAQ: ONC) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $320.00 price target on the stock, up previously from $207.00.
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2025
06:00 am
ONC
beigene, ltd. - american depositary shares
MISS
Report
4.7%
beigene, ltd. - american depositary shares
2/27/2025
06:00 am
ONC
beigene, ltd. - american depositary shares
MISS
Report
4.2%
beigene, ltd. - american depositary shares
2/27/2025
06:00 am
ONC
beigene, ltd. - american depositary shares
MISS
Report
3.9%
beigene, ltd. - american depositary shares
2/27/2025
06:00 am
ONC
beigene, ltd. - american depositary shares
MISS
Report
2.3%
beigene, ltd. - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
05:05 pm
onc
Form 4 BeiGene, Ltd. For: Apr 01 Filed by: Wu Xiaobin
Medium
Report
Form 4 BeiGene, Ltd. For: Apr 01 Filed by: Wu Xiaobin
3/20
04:53 pm
onc
Form 4 BeiGene, Ltd. For: Mar 18 Filed by: Wang Xiaodong
Low
Report
Form 4 BeiGene, Ltd. For: Mar 18 Filed by: Wang Xiaodong
3/18
04:51 pm
onc
Form 4 BeiGene, Ltd. For: Mar 14 Filed by: Wu Xiaobin
Low
Report
Form 4 BeiGene, Ltd. For: Mar 14 Filed by: Wu Xiaobin
3/13
04:44 pm
onc
Form 4 BeiGene, Ltd. For: Mar 11 Filed by: Wang Xiaodong
Low
Report
Form 4 BeiGene, Ltd. For: Mar 11 Filed by: Wang Xiaodong
3/12
05:03 pm
onc
Form 4 BeiGene, Ltd. For: Mar 10 Filed by: OYLER JOHN
Low
Report
Form 4 BeiGene, Ltd. For: Mar 10 Filed by: OYLER JOHN
3/7
08:18 pm
onc
Form 4 BeiGene, Ltd. For: Mar 07 Filed by: OYLER JOHN
Low
Report
Form 4 BeiGene, Ltd. For: Mar 07 Filed by: OYLER JOHN
3/7
07:26 pm
onc
Form 4 BeiGene, Ltd. For: Mar 05 Filed by: OYLER JOHN
Low
Report
Form 4 BeiGene, Ltd. For: Mar 05 Filed by: OYLER JOHN
3/7
07:24 pm
onc
Form 4 BeiGene, Ltd. For: Mar 05 Filed by: Wu Xiaobin
Low
Report
Form 4 BeiGene, Ltd. For: Mar 05 Filed by: Wu Xiaobin
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: